

110

ESCOBAR - URIBE ASOCIADOS

A B O G A D O S

Carrera 11A No. 94 -76 - Of.305 - P.O. Box 94948, Bogotá, D.C. - Colombia

Tels: (571) 6162051 - Fax (571) 6161889

www.escobaruribe.com - info@escobaruribe.com

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

Rad: 03-039889- -00006-0000

Fec: 2007-03-26 11:21:42 Dep. 2020 NUECREACIONES

Tra. 11 PATENTEYII

Eve: 379 FASENACIONALII

Act 593 IMPULSOPROCESAL

Folios: 1

As: 2552/P.

Doctor

GIANCARLO MARCENARO JIMÉNEZ

Superintendente Delegado Para la Propiedad Industrial

EXPEDIENTE: 03-039.889

**ASUNTO: Solicitud de patente a nombre de
Novartis AG.**

Estimado Doctor:

En mi calidad de apoderada de la sociedad solicitante de la patente de la referencia manifiesto a usted lo siguiente:

1. Mediante memorial radicado en ese despacho el 28 de marzo 2005, el cual no ha sido resuelto aún, solicité que se realizara el examen de patentabilidad.
2. En vista de que han transcurrido **1 año y 9 meses** sin que se haya atendido dicha solicitud, ruego a usted se sirva dar las instrucciones del caso para que se proceda de inmediato a resolver este asunto.

Cordialmente,


JIMENA ESCOBAR URIBE
CC 39.779.452 de Usaquén.
T.P. 68228



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 45/06, 31/535 // (A61K 31/535 A61K 31/40)		A1	(11) International Publication Number: WO 91/17771 (43) International Publication Date: 28 November 1991 (28.11.91)
(21) International Application Number: PCT/US91/02733 (22) International Filing Date: 22 April 1991 (22.04.91) (30) Priority data: 522,360 11 May 1990 (11.05.90) US (60) Parent Application or Grant (63) Related by Continuation US 522,360 (CIP) Filed on 11 May 1990 (11.05.90) (71) Applicant (for all designated States except US): PFIZER INC. [US/US]; Eastern Point Road, Groton, CT 06340 (US).		(72) Inventor; and (73) Inventor/Applicant (for US only) : FOSSA, Anthony, An- drea [US/US]; 36 Boom Bridge Road, North Stoning- ton, CT 06359 (US). (74) Agents: LUMB, J., Trevor et al.; Pfizer Inc., Eastern Point Road, Groton, CT 06340 (US). (81) Designated States: AT (European patent), AU, BE (Euro- pean patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CM (OAPI patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (Eu- ropean patent), GR (European patent), HU, IT (Euro- pean patent), JP, KR, LK, LU (European patent), ML (OAPI patent), MR (OAPI patent), NL (European pa- tent), NO, PL, RO, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent), US. Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(54) Title: SYNERGISTIC THERAPEUTIC COMPOSITIONS AND METHODS			
(57) Abstract This invention relates to compositions and methods for achieving a therapeutic effect such as lowering blood pressure and treating congestive heart failure in a mammal. More specifically, this invention relates to synergistic compositions comprising amounts of at least two therapeutic agents selected from the group consisting of a renin inhibitor, an angiotensin I converting enzyme inhibitor and an angiotensin II antagonist, which inhibitors and antagonists are present in amounts sufficient to cause synergistic therapeutic effects such as lowering blood pressure and treating congestive heart failure in a mammal. Further, this invention relates to methods for achieving synergistic therapeutic effects such as lowering blood pressure and treating congestive heart failure in a mammal which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from the group consisting of a renin inhibitor, an angiotensin I converting enzyme inhibitor and an angiotensin II antagonist, in amounts sufficient to achieve a synergistic therapeutic effect.			

-21-

CLAIMS

1. A method for achieving a synergistic therapeutic effect in a mammal in need thereof which comprises administering to said mammal amounts of at least two therapeutic agents selected from the group consisting of:

- (a) a renin inhibitor;
- (b) an angiotensin I converting enzyme inhibitor;

and

- (c) an angiotensin II antagonist,

wherein the amount of (a) alone, the amount of (b) alone and the amount of (c) alone is insufficient to achieve the therapeutic effect; and

wherein the combined effect of the amounts of the therapeutic agents administered is greater than the sum of the therapeutic effects of the amounts of the individual therapeutic agents administered.

2. The method according to claim 1 wherein an amount of a renin inhibitor and an amount of an angiotensin I converting enzyme inhibitor are administered simultaneously.

3. The method according to claim 2 wherein the renin inhibitor is $\{\alpha\text{-R}[\alpha\text{-R}^*, \beta\text{-S}^*(\text{S}^*, \text{S}^*)]\text{-}\alpha\text{-hydroxy-}\beta\text{-}[[2\text{-}[[2\text{-}(4\text{-morpholin-1-carboxamido})\text{-1-oxo-3-phenylpropyl]amino}]\text{-3-methylthio-1-oxo-propyl}]\text{-amino}]\text{cyclohexanebutanoic acid}$, and the angiotensin I converting enzyme inhibitor is captopril, enalapril, lisinopril or ramipril.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A01N 43/64, A61K 31/41, 31/415	A1	(11) International Publication Number: WO 92/10097 (43) International Publication Date: 25 June 1992 (25.06.92)
(21) International Application Number: PCT/US91/09362 (22) International Filing Date: 13 December 1991 (13.12.91) (30) Priority data: 628,807 14 December 1990 (14.12.90) US (60) Parent Application or Grant (63) Related by Continuation US 628,807 (CIP) Filed on 14 December 1990 (14.12.90) (71) Applicant (for all designated States except US): SMITH-KLINE BEECHAM CORPORATION [US/US]; Corporate Patents - U.S., 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406 (US).	(72) Inventor; and (75) Inventor/Applicant (for US only) : WEINSTOCK, Joseph [US/US]; 1234 Pothouse Road, Phoenixville, PA 19460 (US). (74) Agents: McCARTHY, Mary, E. et al.; SmithKline Beecham Corporation, Corporate Patents - U.S. (UW2220), 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), MC (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS (57) Abstract This invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier, an angiotensin II receptor antagonist and a second agent selected from a diuretic, a calcium channel blocker, a β -adrenoceptor blocker, a renin inhibitor, or an angiotensin converting enzyme inhibitor and a method of treating hypertension.		

5

10

- 1 -

15 ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONSFIELD OF INVENTION

20 This invention relates to pharmaceutical compositions comprising angiotensin II receptor antagonists, combined with other agents, particularly diuretics, calcium channel blockers, β -adrenoceptor blockers, renin inhibitors, or angiotensin converting enzyme inhibitors. The invention also relates to a method of treating hypertension by administering said

25 compositions to a subject in need thereof or by stepwise combined therapy.

BACKGROUND OF THE INVENTION

30 The class of peptide pressor hormone known as angiotensin is responsible for a vasopressor action that is implicated in the etiology of hypertension in man. Inappropriate activity of the renin-angiotensin systems appears to be a key element in essential hypertension, congestive heart failure and in some forms of renal

35 disease. In addition to a direct action on arteries and arterioles, angiotensin II (AII), being one of the most potent endogenous vasoconstrictors known, exerts
